Table 1. Description of patients with Parkinson’s disease.

patient	Age [years]	DD [years]	levodopa [mg]	UPDRS III	H-Y	DBS target	task	neurons
1	64	14	1375	31	2.0	STN	SEM	12
2	61	14	1200	37	2.5	STN	SEM	7
3	46	15	1000	40	3.0	STN	SEM	15
4	63	30	1250	50	3.0	STN	SEM	3
5	53	12	700	37	2.5	STN	SEM	14
6	69	9	750	47	3.0	STN	SEM	5
7	49	12	1550	65	4.0	STN	SEM	7
8	59	12	600	30	2.5	STN	SEM	8
9	63	14	1350	21	2.0	GPi	SEM	4
10	53	10	750	42	4.0	GPi	SEM	11
11	53	11	1663	45	2.5	STN	SEM	5
12	57	26	2000	59	4.0	STN	SEM	12
13	28	3	720	10	2.0	GPi	SEM	6
14	64	17	1500	31	2.5	STN	SEM	12
15	53	12	1000	40	4.0	STN	SEM	9
16	44	10	1130	23	2.0	GPi	SEM, VGS	2
17	42	9	740	33	3.0	STN	SEM, VGS	20
18	55	19	1980	35	2.0	STN	SEM, VGS	16
19	60	14	1060	18	2.0	STN	SEM, VGS	15

Age – age on the day of surgery; STN – subthalamic nucleus; GPi – globus pallidus interna; DD – Parkinsońs disease duration; Levodopa – dose/day in mg including levodopa equivalent dosage of dopamine agonist; patient 4 was also treated with mianserin; patients 6, 7, 8, 9, 10 with citalopram and 16 with bupropion; UPDRS III – motor score of the Unified Parkinsońs Disease Rating Scale in OFF medication condition; H-Y – Hoehn and Yahr stage in OFF medication condition; DBS target – nucleus chosen for bilateral deep brain stimulation; SEM – scanning eye movement task; VGS – visually guided saccade task; neurons – number of neurons identified in the basal ganglia.